Table 2.
Propensity score matched cohort (1:1) characteristics. Clinical characteristics of 5,960 patients on warfarin vs 5,960 patients not on warfarin after dialysis transition.
| Variable | No Warfarin After Transition n = 5,960 | Warfarin After Transition n = 5,960 | Standardized Difference |
|---|---|---|---|
| Age, years, Mean ± SD | 74 ± 9 | 74 ± 9 | −0.01 |
| Female, n (%) | 213 (4) | 243 (4) | 0.03 |
| Race | |||
| White, n (%) | 4,956 (83) | 4,903 (82) | −0.02 |
| African American, n (%) | 877 (15) | 906 (15) | 0.01 |
| Hispanic, n (%) | 181 (3) | 228 (4) | 0.04 |
| Other, n (%) | 127 (2) | 151 (3) | 0.03 |
| Comorbidities | |||
| Cerebrovascular disease, n (%) | 3,235(54) | 3,259(55) | 0.0081 |
| Myocardial infraction, n (%) | 2,747(46) | 2,683(45) | −0.0216 |
| Peripheral vascular disease, n (%) | 3,918(66) | 3,872(65) | −0.0162 |
| Ischemic heart disease, n (%) | 5,126(86) | 5,068(85) | −0.0277 |
| Hypertension, n (%) | 5,930(99) | 5,911(99) | −0.0398 |
| Congestive heart failure, n (%) | 5,247(88) | 5,171(87) | −0.0385 |
| Diabetes, n (%) | 4,696(79) | 4,648(78) | −0.0196 |
| Liver Disease, n (%) | 1,133(19) | 1,137(19) | 0.0017 |
| Cancer, n (%) | 2,095(35) | 2,104(35) | 0.0032 |
| CHA2DS2-VASC Score, median (IQR) | 6 (5,7) | 6 (5,7) | 0.01 |
| HAS-BLED Score, median (IQR) | 3 (3,4) | 3 (3,4) | 0.01 |